fda approved glp 1 agonists Glucagon-like peptide receptor (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. http://ms.spr.ly/6188SW4Iw Bariatric Happy Hour! A cost
Description
Acta Neurol Scand 2010

The answer explains nearly everything else, from how much weight people lose to which side effects appear to what metabolic benefits extend beyond the scale

[DOI] [PubMed] [Google Scholar] [92].Pan SY, Su EL, Huang CJ, Chuang SY, Chiang CE, Chen CH, et al

The case settled in March 2026: Novo dropped the lawsuit in exchange for Hims agreeing to transition its platform entirely to authorized, branded semaglutide products and to cease all advertising of compounded GLP-1 alternatives
